By Editorial TeamIf you follow the money in cardiac AI, it flows in two completely different directions. The capital reveals two separate economies, not one. There’s the economy of detection and diagnostics, and then there’s the much smaller, less-funded economy of prevention. For investors or anyone sponsoring a prevention program, understanding this split in investment patterns is the key to making sense of the cardiovascular AI space.
The Skewed Capital Allocation: Detection Dominates Funding
A quick look at investment in cardiac AI shows exactly where the money is going: diagnostics. Around 90 percent of all recorded funding goes to tech that detects and diagnoses cardiovascular conditions, according to a Rock Health funding report. This pile of cash shows a mature market where investors see clear reimbursement pathways for diagnostic tools that can just slot into existing clinical workflows and billing. Companies like HeartFlow, which uses AI to build 3D models of coronary arteries from CT scans to check blood flow (CT-FFR), and iRhythm Technologies with its AI-driven wearable ECG monitors for arrhythmia, are the poster children for this detection economy. Both are public companies that benefit from established regulatory pathways (like 510(k) clearance or the De Novo classification for novel devices through the FDA) and existing CPT codes that make it easy to get paid by traditional payers. Their whole business is built around the diagnostic pipeline, offering tools that improve or flat-out replace old ways of identifying disease. The core technology, cardiac risk prediction models, is actually shared by both the detection and prevention sides. But how they’re used and sold couldn’t be more different. The detection economy focuses on high-acuity settings or tricky diagnostic cases where the immediate effect on a patient’s treatment plan, and the potential cost savings from a better diagnosis, are easy to measure. This focus leads investors to back technologies with strong clinical validation and an obvious path into today’s healthcare infrastructure.
The Prevention Economy: A Different Reimbursement Model
The prevention side of cardiac AI gets a tiny fraction of the capital that detection does, even though it’s targeting a massive population of tens of millions of Americans, based on KFF data on chronic disease prevalence. This part of the market is all about proactive health management and lowering risk before a major cardiac event happens. The big problem for these prevention-focused AI platforms is how to get paid, since they usually have to work around traditional CMS reimbursement. Hello Heart is a great example. They operate on an employer-funded model, giving people tools and insights to manage their heart health with the goal of stopping cardiovascular disease before it starts or gets worse. This approach lets them sidestep the headaches and delays that come with medical billing and reimbursement codes by engaging directly with employers or plan sponsors. And it works. The company’s success in raising $138 million total, including a $70 million Series D round led by Stripes Group, shows that this alternative funding model can actually scale a prevention business. This model lets Hello Heart go after the huge, underserved group of people at risk for heart disease, giving them a scalable solution outside the walls of fee-for-service medicine.
Public Markets and Private Capital: Divergent Paths to Scale
The way these companies get money also separates them. The detection economy, with companies like HeartFlow and iRhythm Technologies, leans on public market capital to grow. These companies have to manage the expectations of public shareholders, and their valuations are often directly connected to market penetration, how much revenue they’re getting from diagnostic procedures, and whether they’re hitting their regulatory milestones. Their massive, proprietary datasets of patient ECGs and imaging data create a powerful data moat that makes it very difficult for new entrants to compete on accuracy or clinical proof. On the other hand, the prevention economy is mostly attracting private venture capital through funding rounds, which points to a different risk-reward calculation for investors. Is the upside worth the different kind of risk? The employer-funded model used by platforms like Hello Heart has a completely different sales cycle and value proposition, one that’s all about long-term health outcomes, lower healthcare costs for the company, and better employee well-being. This requires a crystal-clear ROI pitch to corporate buyers, not to patients or insurance companies. Rock Health’s ongoing tracking of digital health funding makes this investment imbalance plain as day, showing exactly where the bulk of venture capital flows.
Cardiac AI: Two Distinct Investment Theses
In the end, cardiac AI isn’t one market. It’s two, running on distinct economic engines. While they both use cardiac risk prediction models, their financing, who they sell to, and how they make money are fundamentally different. The detection economy is well-funded, often publicly traded, and focused on improving diagnostics inside existing clinical pathways where reimbursement is already figured out. The prevention economy, while much less capitalized, presents a powerful opportunity to improve population health through employer-funded models that get around traditional reimbursement problems and aim for a huge market of people trying to proactively manage their health. For investors and prevention program sponsors, you have to know which of these two games you’re playing. It’s the only way to identify real opportunities, assess risk correctly, and deploy capital effectively in the far-reaching field of cardiovascular AI.
Frequently Asked Questions
Why is the majority of investment in cardiac AI directed towards detection and diagnostics rather than prevention?
Investment in cardiac AI is skewed towards detection and diagnostics because these solutions often have clearer reimbursement pathways and integrate more easily into existing clinical workflows and billing structures. Companies in this sector benefit from established regulatory frameworks and CPT codes that facilitate reimbursement from traditional payers, making them perceived as having more mature market opportunities.
What are the key differences in commercialization models between cardiac AI for detection and cardiac AI for prevention?
Cardiac AI for detection often targets high-acuity settings and integrates into existing healthcare infrastructure, relying on traditional CMS reimbursement. In contrast, cardiac AI for prevention frequently bypasses traditional CMS reimbursement, instead utilizing alternative models such as direct-to-employer or plan sponsor engagement, as exemplified by companies like Hello Heart.
How do companies in the cardiac AI detection economy achieve scale and secure funding?
Companies in the cardiac AI detection economy, such as HeartFlow and iRhythm Technologies, largely rely on public market capital for growth and expansion. Their valuations are often tied to market penetration, revenue growth from diagnostic procedures, and regulatory milestones, benefiting from extensive proprietary datasets that provide a competitive advantage.
What is the primary funding mechanism for cardiac AI prevention platforms, and what is their value proposition?
Cardiac AI prevention platforms, like Hello Heart, primarily attract venture capital through private funding rounds and often utilize an employer-funded model. Their value proposition emphasizes long-term health outcomes, reduced healthcare costs for employers, and improved employee well-being, requiring a clear articulation of ROI to corporate buyers.
